A daughter’s cancer journey shows that survivorship is filled with constant waiting—from tests and treatment to life ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

Pancreatic cancer accounts for a disproportionate number of cancer-related deaths relative to its incidence, reflecting its aggressive biology and limited treatment options. Most cases are exocrine ...

Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial This is a US Government ...

Partitioned survival modeling estimated OS 66.1 vs 57.8 months and PFS 40.2 vs 31.8 months for durvalumab vs placebo, with substantially higher total costs. Economic results showed durvalumab cost ...

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...

Women with stage IV breast cancer detected through screening have a 60% chance of survival ten years after diagnosis. This is in comparison to a survival rate of under 20% of those with stage IV ...

A new hope for those with cancer. Cancer survival rates have reached new heights, with 70% of patients diagnosed hitting the five-year survival mark. Now, new research shows one particular habit could ...

The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer in conjunction with the drugs gemcitabine and nab-paclitaxel. The approval ...

A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic ...